Understanding Alzheimer’s – From discovery research to patient treatment

Livewire Exclusive

Livewire Markets

Positive results announced by Biogen, Anavex, and Lilly, along with Avanir's acquisition by Otsuka Pharma for US$3.5 billion have sparked renewed investor interest in Alzheimer’s drugs. Earlier this year, Axovant, a clinical-stage biotech focused on dementia treatments, pulled off one of the biggest biotech IPO in history with shares almost doubling on their first day of trade. These events reflect the enormous need to develop an effective treatment for Alzheimer’s disease. Actinogen Medical (ASX:ACW) invites Livewire readers to an investor event to learn more about Alzheimer’s disease and the companies working on a cure for Alzheimer’s. Please join us for a panel discussion and short presentations from leading industry, scientific and medical professionals including Eli Lilly, Alzheimer’s Australia and the Garvan Institute of Medical Research. This investor event will be held on Monday, October 12 at the Sofitel Hotel in Sydney from 4.30pm. Drinks and Canapés provided. To register your interest please click on this (VIEW LINK) . See the attached flyer for more information.

2 topics

1 stock mentioned

Livewire Exclusive brings you exclusive content from a wide range of leading fund managers and investment professionals.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.